• Textsize Middle
  • Textsize Large






Respiratory Molecular Medicine

Subject Respiratory Molecular Medicine
Koichi Takayama
 Associate Professor    Junji Uchino
 Lecturer                    Tadaaki Yamada
 Assistant Professor     Yoshiko Kaneko
 Assistant Professor     Nobuyo Tamiya
Research Contents

Clinical research
1. Endoscopic treatment
2. Medical thoracoscopy
3. Chemotherapy for advanced lung cancer
4. Chemoradiotherapy for locally advanced lung cancer
5. Target therapy for advanced lung cancer
6. Biomarker for lung cancer
7. Treatment for Asthma
8. Treatment for COPD
9. Diagnosis of sleep apnea syndrome
10. Bronchial embolization for refractory pneumothorax


Experimental research
1. Mechanism of acute lung injury development
2. Mechanism of obstructive lung disease development
3. Mechanism of interstitial lung disease development
4. Mechanism of lung cancer development
5. Mechanism of cancer-associated cachexia
6. Liquid biopsy for lung cancer
7. Novel therapeutic approach for lung cancer
8. Immunotherapy of lung cancer

Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 80: 45-49, 2013.

Okamura K, Nagata N, Wakamatsu K, Yonemoto K, Ikegame S, Kajiki A, Takayama K, Nakanishi Y. Hypoalbuminemia and lymphocytopenia are predictive risk factors for in-hospital mortality in patients with tuberculosis. Inter Med 52: 439-444, 2013.
Yamada K, Takayama K, Kawakami S, Saruwatari K, Morinaga R, Harada T, Aragane N, Nagata S, Kishimoto J, Nakanishi Y, Ichinose Y. Phase II trial of erlotinib for Japanese patients with previousky treated non-small-cell lung cancer harboring EGFR mutations: Results of Lung Oncology Group in Kyushu(LOGiK0803) Jpn J Clin Oncol 43: 629-635, 2013.
Takayama K**, Inoue K, Tokunaga S, Mastumoto T, Oshima T, Kawasaki M,Imanaga T, Kuba M, Takeshita M, Harada T, Shioyama Y, Nakanishi Y. Phase IIstudy of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer:LOGIK0401. Cancer Chemother Pharmacol 72: 1353-1359, 2013.
Kang JH, Mori T, Kitazaki H, Niidome T, Takayama K, Nakanishi Y, Katayama Y. Serum protein kinase Cα as a diagnostic biomarker of cancers. Cancer Biomark 13: 99-103, 2013.
Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thoracic Oncol 8: 753-8, 2013.
Kang JH, Mori T, Kitazaki H, Niidome T, Takayama K, Nakanishi Y, Katayama Y. Kinase activity of protein kinase cα in serum as a diagnostic biomarker of human lung cancer. Anticancer Res 33: 485-8, 2013.
Takeshita M, Koga T, Takayama K, Ijichi K, Yano T, Maehara Y, Nakanishi Y, Sueishi K. Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer 80: 85-90, 2013.
Wang S, Takayama K, Tanaka K, Takeshita M, Nakagaki N, Ijichi K, Li H, Nakanishi Y. Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by 1 nicotinic acetylcholine receptor-mediated activation in PC9 cells. J Thorac Oncol 8: 719-725, 2013.
Furuyama K, Harada T, Iwama E, Shiraishi Y, Okamura K, Ijichi K, Fujii A, Ota K, Wang S, Li H, Takayama K, Giaccone G, Nakanishi Y. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci 104: 584-9, 2013.
Harada T, Hamada A, Shimokawa M, Takayama K, Kudoh S, Maeno K, Saeki S, Miyawaki H, Moriyama A, Nakagawa K, Nakanishi Y. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer. Jpn J Clin Oncol 44: 127-33, 2014.
Katakami N, Kunikane H, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, Yokota I, Ohashi Y, Eguchi K. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thoracic Oncol 9: 231-8, 2014.
Narusawa M, Inoue H, Sakamoto C, Matsumura Y, Takahashi A, Inoue T, K Watanabe A, Miyamoto S, Miura Y, Hijikata Y, Tanaka Y, Inoue M, Takayama K, Okazaki T, Hasegawa M, Nakanishi Y, Tani K. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells. Cancer Immunol Res 2: 568-580, 2014.
Okamoto I, Sakai K, Morita S, Yoshioka H, Kaneda H, Takeda K, Hirashima T, Kogure Y, Kimura T, Takahashi T, Atagi S, Seto T, Sawa T, Yamamoto M, Satouchi M, Okuno M, Nagase S, Takayama K, Tomii K, Maeda T, Oizumi S, Fujii S, Akashi Y, Nishino K, Ebi N, Nakagawa K, Nakanishi Y, Nishio K. Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget 5: 2293-2304, 2014.
Ikesue H, Tsuji T, Hata K, Watanabe H, Mishima K, Uchida M, Egashira N, Miyamoto T, Baba E, Akashi K, Takayama K, Nakanishi Y, Tokunaga E, Okamoto T, Maehara Y, Yokomizo A, Naito S, Kubo M, Tanaka M, Masuda S:Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. Ann Pharmacother 48: 1159-1165, 2014.
Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer. Ann Oncol 25:1935-1940, 2014
Li H, Takayama K, Wang S, Shiraishi Y, Gotanda K, Harada T, Furuyama K, Iwama E, Ieiri I, Okamoto I, Nakanishi Y.Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Cancer Chemother Pharmacol. 74:1297-305, 2014.
Okamura K, Takayama K, Kawahara K, Harada T, Nishio M, Otsubo K, Ijichi K, Kohno M, Iwama E, Fujii A, Ota K, Koga T, Okamoto T, Suzuki A, Nakanishi Y. PICT1 expression is a poor prognostic factor in non-small cell lung cancer. Oncoscience. 1:375-82, 2014.
Li H, Wang S, Takayama K, Harada T, Okamoto I, Iwama E, Fujii A, Ota K, Hidaka N, Kawano Y, Nakanishi Y. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Lung Cancer. 88:1-8, 2015.
Nakahara T, Moroi Y, Takayama K, Itoh E, Kido-Nakahara M, Nakanishi Y, Furue M.Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors. Onco Targets Ther. 28;259-63, 2015.
Fujii A, Harada T, Iwama E, Ota K, Furuyama K, Ijichi K, Okamoto T, Okamoto I, Takayama K, Nakanishi Y. Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer. Cancer Genet. 208:271-8, 2015.
Nakahara T, Moroi Y, Takayama K, Nakanishi Y, Furue M. Analysis of sebum lipid composition and the development of acneiform rash before and after administration of egfr inhibitor. Curr Oncol. 22:e124-7, 2015.
Iwama E, Takayama K, Harada T, Okamoto I, Ookubo F, Kishimoto J, Baba E, Oda Y, Nakanishi Y. Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. Oncotarget. Epub 2015
Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Epub 2015
Ikesue H, Watanabe H, Hirano M, Chikamori A, Suetsugu K, Ryokai Y, Egashira N, Yamada T, Ikeda M, Iwama E, Harada T, Takayama K, Nakanishi Y, Masuda S. Risk factors for predicting severe neutropenia induced by pemetrexed plus carboplatin therapy in patients with advanced non-small cell lung cancer.
Biol Pharm Bull. 38:1192-8, 2015
Tsubouchi K, Hamada N, Ijichi K, Umezaki T, Takayama K, Nakanishi Y. Spontaneous improvement of laryngeal sarcoidosis resistant to systemic corticosteroid administration. Respirol Case Rep. 3:112-4, 2015
Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, Komura N, Eguchi K. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 24:3495-505, 2016
Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.
Support Care Cancer. 24:3473-80, 2016
Fujita M, Matsumoto T, Inoue Y, Wataya H, Takayama K, Ishida M, Ebi N, Kishimoto J, Ichinose Y; Lung Oncology Group in Kyushu (LOGIK). The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study. J Infect Chemother. 22:235-9, 2016
Iwama E, Okamoto I, Yabuuchi H, Takayama K, Harada T, Matsuo Y, Tokunaga S, Baba E, Nakanishi Y. Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae. J Thorac Oncol. 2016 May 7. epub
Yamada K, Azuma K, Takeshita M, Uchino J, Nishida C, Suetsugu T, Kondo A, Harada T, Eida H, Kishimoto J, Eriguchi G, Takayama K, Nakanishi Y, Sugio K. Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
Anticancer Res. 36:2881-7, 2016
Takayama K, Sugawara S, Saijo Y, Maemondo M, Sato A, Takamori S, Harada T, Sasada T, Kakuma T, Kishimoto J, Yamada A, Noguchi M, Itoh K, Nakanishi Y. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. J Immunol Res. 2016 epub
Contact tel 81-75-251-5513
fax 81-75-251-5376
e-mail takayama@koto.kpu-m.ac.jp
HP http://kokyu-kpum.com/

602-8566 Kyoto-shi, Kamigyo-ku Kajii-cho,
Kawaramachi-Hirokoji, JAPAN